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INTRODUCTION
Over the past two decades, HIV has
emerged as a global public health pandemic, to
become a modern day “plaque”. Tuberculosis
(TB) is a disease of great antiquity and  remains
a major challenge worldwide both in terms of
disease burden and resistance to conventional
antibiotic therapy (Eltringham and Drobniewski,
1998). The rising incidence of TB due to the ef-
fect of HIV in both developed and developing
countries is well recognized (Narain et al, 1992).
In Malaysia, tuberculosis is among the top 5
communicable diseases. The number of reported
cases of tuberculosis and HIV coinfection have
increased from 6 cases in the year 1990 to 933
cases in the year 2002 (Ministry of Health Ma-
laysia, 2002). Infection with HIV has modified the
epidemiology, pathogenesis and clinical mani-
festations of tuberculosis (Pulido et al, 1997) and
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Abstract. This retrospective study was conducted at the National Tuberculosis Center (NTBC) where
252 HIV-positive patients coexisting with tuberculosis (TB/HIV) were examined.  We found that pa-
tients with pulmonary (PTB) and extrapulmonary tuberculosis (EPT) had similar mean age. A higher
sex ratio between male to female (10.7:1) was observed in patients with PTB. The other character-
istics of patients with pulmonary and extrapulmonary tuberculosis were not statistically different
from each other. Cough (88%) and hemoptysis were the most common presenting symptoms, sig-
nificantly related to patients with PTB. Lymphadenopathy (33.5%) was the most common sign in
patients with EPT. The majority of patients with pulmonary and extrapulmonary tuberculosis had
CD4 cell counts of less than 200 cells/mm3 (range 0-1,179 with a median of 57 cells/mm3). Lung
(89%) and miliary (55.6%) forms were the most frequent disease locations in patients with PTB and
EPT, respectively. A higher percentage of patients with PTB (42%) were treated successfully with
short-course (6 months) therapy, whereas in patients with EPT (43%) needed a longer period (9
months) for successful treatment. Of the patients who defaulted treatment, a higher proportion (87%)
had PTB. No MDR-TB or relapse cases were found in this study.
is by far the most important risk factor known
for the progression of latent M. tuberculosis in-
fection to active TB and for the rapid progres-
sion of new infection to TB (Johnson and Ellner,
1999). TB now is the leading opportunistic in-
fection causing death in HIV-infected persons
globally, accounting for about 44% of all AIDS-
related deaths annually (Jones et al, 1999). We
conducted this study in order to compare the
characteristics of HIV-positive patients with pul-
monary and extrapulmonary tuberculosis, and
to describe the organ involvement, clinical diag-
nosis and treatment outcomes.
MATERIALS AND METHODS
Patients. A total of 252 HIV-positive patients reg-
istered for tuberculosis treatment from 1 Janu-
ary 2001 to 31 December 2002 at the National
Tuberculosis Center (NTBC) were included in this
study. This center is a tertiary level national ref-
erence center for respiratory diseases situated
in Kuala Lumpur, Malaysia. Any person with a
respiratory problem can attend this center with-
out a physician referral. Majority of notified TB
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cases in Kuala Lumpur territory each year are
treated. The data were retrospectively reviewed
from each patient’s medical record. Socio-de-
mographic profiles, clinical presentations, inves-
tigation results, treatment, patient compliance
with therapy, and outcomes of therapy response
were included in a standardized data collection
sheet. AIDS defining illnesses were also based
on the 1993 CDC classification.
The case definitions were obtained from the
World Health Organization (WHO, 2002).
A case of tuberculosis was defined as a
patient in whom tuberculosis has been bacte-
riologically confirmed, or has been diagnosed by
a clinician.
A pulmonary tuberculosis, sputum smear
positive (PTB+) case was defined as two or more
initial sputum smear examinations positive for
Acid-Fast Bacilli (AFB) or one sputum smear
examination positive for AFB plus radiological
abnormalities consistent with active pulmonary
tuberculosis as determined by a clinician, or one
sputum smear positive for AFB plus sputum cul-
ture positive for M. tuberculosis.
A pulmonary tuberculosis, sputum smear
negative (PTB-) case was defined as a case of
pulmonary tuberculosis which does not meet the
above definition for smear positive TB. In keep-
ing with good clinical and public health practices,
diagnostic criteria should include: at least three
sputum specimens negative for AFB, and radio-
graphic abnormalities consistent with active pul-
monary tuberculosis, and no response to a
course of broad spectrum antibiotics, and deci-
sion by a clinician to treat with a full course of
anti-tuberculosis chemotherapy.
An extrapulmonary tuberculosis case was
defined as tuberculosis of organs other than the
lungs, such as pleura, lymph nodes, abdomen,
genitourinary tract, skin, joints, bones, and
meninges. Disease should be based on one cul-
ture positive specimen, or histological or strong
cl in ica l  ev idence consistent with act ive
extrapulmonary tuberculosis, followed by a de-
cision by a clinician to treat with a full course of
anti-tuberculosis chemotherapy.
Categories of patients for registration
New: A patient who has never had treat-
ment for TB or has taken anti-tuberculosis drugs
for less than one month.
Relapse: A patient previously treated for TB
who has been declared cured or has completed
treatment, and is diagnosed with bacteriologi-
cally positive (smear or culture) tuberculosis.
Failure: A patient who, while on treatment,
is sputum smear positive at 5 months or later
during the course of treatment.
Return after default: A patient who returns
for treatment with positive bacteriology, follow-
ing an interruption of treatment for two or more
months.
Transfer in: A patient who has been trans-
ferred from another tuberculosis register to con-
tinue treatment.
Categories of treatment outcomes
Cure: A patient who is sputum smear nega-
tive in the last month of treatment and on at least
one previous occasion.
Treatment completed: A patient who has
completed treatment but who does not meet the
criteria to be classified as cured or a failure.
Treatment failure: A patient who is sputum
smear positive at five months or later during
treatment.
Died: A patient who dies for any reason
during the course of treatment.
Defaulter: A patient whose treatment was
interrupted for 2 or more consecutive months.
Transfer out: A patient who has been trans-
ferred to another unit and for whom the treat-
ment outcome is not known.
Treatment success: A patient who is cured
and who has completed treatment.
Statistical analysis
The data was analyzed by using the statis-
tical software, SPSS version 10. (SPSS Inc, Chi-
cago, Ill, USA). The data with quantitative vari-
ables were expressed by mean (± SD) and range
while the qualitative variables were estimated by
frequency and percentage. Statistical analysis
was estimated using either the chi-square test
or Student’s t-test where appropriate. Further
analysis using the multiple logistic regression was
employed to determine the predictors of type of
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tuberculosis. A p-value of <0.05 was regarded
as statistically significant.
RESULTS
Table 1 demonstrates the socio-demo-
graphic characteristics of 252 TB/HIV patients.
One hundred and ninety-eight patients were di-
agnosed as having pulmonary tuberculosis (PTB)
including only PTB or PTB with its dissemina-
tion; while the other 54 patients were diagnosed
as having extrapulmonary tuberculosis (EPT). We
found that patients with PTB and EPT were simi-
lar in their mean ages. A sex ratio between males
and females (10.7:1) was apparently higher in
patients with PTB. The other characteristics of
patients with pulmonary and  extrapulmonary tu-
berculosis showed no statistically significant dif-
ferences between the two groups. A higher per-
centage of smoking and/or drinking alcohol, his-
tory of previous tuberculosis, and history con-
tact with TB patients was seen in patients with
PTB.
Cough (88%), loss of weight and/or appe-
tite (82%), and fever (73%) were the most  com-
mon presenting symptoms in patients with PTB.
There were significant associations between
cough, sputum and hemoptysis with PTB pa-
tients (p<0.05). Multiple logistic regressions
showed that only cough and hemoptysis were
significantly associated with PTB patients. Lym-
phadenopathy (33.5%) was the most common
sign in patients with EPT. Majority of 35 patients
with pulmonary and extrapulmonary tuberculo-
sis had CD4 cell counts of less than 200 cells/
mm3 (range 0-1,179 with a median of 57 cells/
mm3) at the time of diagnosis. We were unable
to obtain the CD4 cell count of the other pa-
tients as they were being jointly managed with
infectious Disease units located in other hospi-
tals. Lung (89%) was the most frequent disease
location in patients with PTB, whereas the mil-
iary (55.6%) form was the most common in pa-
tients with EPT, as shown in Tables 2 and Fig 1,
respectively.
Table 3 illustrates that among the 252 TB
patients, the 6 month anti-tubercular therapy
regimen was the most common successful regi-
men for both types of TB patient; but had a
Table 1
The socio-demographic characteristics of
252 TB/HIV patients attending the  National
Tuberculosis Center, January 2001 to
December 2002.
Variables PTB (198) EPT (54) p-value
n (%) n (%)
Range of ages    18-68 years 23-82 years
Mean ± SD    37.2±7.8     38.9±9.5    0.168
Sex ratio (M:F)    10.7:1     6.7:1
Age group (years) 0.744
≤ 24     7 (3.5)     3 (5.6)
25-34   72 (36.4)   15 (27.8)
35-44   83 (42)   26 (48.2)
45-54   31 (15.7)     8 (14.8)
≥ 55    5 (2.5)     2 (3.7)
Sex 0.331
Male 181 (91.4)   47 (87)
Female   17 (8.6)     7 (13)
Race 0.114
Malay 120 (60.6)   24 (44.4)
Chinese   38 (19.2)   18 (33.3)
Indian   28 (14.1)     9 (16.7)
Othersa   12 (6.1)     3 (5.6)
Marital status 0.904
Single 141 (71)   38 (70)
Married   57 (29)   16 (30)
Address 0.389
Kuala Lumpur   90 (44.5)   21 (38.9)
Outsider 108 (54.5)   33 (61.1)
Occupation
Laborer   35 (17.7)     4 (7.4)    0.170
Nonlaborer   26 (13.1)     7 (13)
Unemployed 137 (69.2)   43 (79.6)
Risk factors of HIV transmission 0.875
Heterosexual      61 (30.8)     19 (27.8)
Homosexual        2 (1) -
Intravenous drug use 145 (73.2)     39 (72.2)
Not known       1 (0.5) -
Smoking 0.773
Yes     86 (43.4)     22 (40.7)
No   112 (56.6)     32 (59.3)
Drinking alcohol
Yes       9 (4.6)       4 (7.4)    0.399
No   189 (95.4)     50 (92.6)
Case categoryb 0.006
New case   173 (87.4)     54 (100)
History of previous tuberculosis
Relapse 11 (5.6) -
Return after defaulted 14 (7.1) -
History of contact with tuberculosis patients 0.140
Yes     20 (10)      2 (3.7)
No 178 (90)    52 (96.3)
aOther: foreigners who were classified as persons with
foreign nationality and persons with first and/or family
names that were clearly not Malaysian.
bp< 0.05 for differences between PTB and ETB groups
by χ2 test.
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Table 2
Clinical manifestations and investigations of 252 TB/HIV patients.
Variables PTB (198) n (%) EPT (54) n (%)
Symptoms
Cougha 175 (88.4) 30 (55.6)
Loss of appetite and/or weight 163 (82.3) 40 (74.1)
Fever 145 (73.2)      33 (61)
Sputuma 102 (51.5)      18 (33.3)
Dyspnea   53 (26.8) 12 (22.2)
Pain (chest, back, and abdomen)  47 (23.7)   9 (16.7)
Hemoptysisa  38 (19.2) 4 (7.4)
Dysphagia        2 (1)        1 (2)
Signs
BCG vaccination status
Yes 108 (54.5)       34 (63)
No 23 (11.5)  3 (5.5)
No information 67 (34)  17 (31.5)
Tuberculin skin test (Mantoux test)
Positive (≥ 10 mm)   25 (12.6)       14 (26)
Negative (< 10 mm)   34 (17.2)  6 (11)
No information 139 (70.2)       34 (63)
Lymphadenopathya
Cervical   29 (14.7)  17 (31.5)
Supraclavicular         2 (1)            -
Other site - -
Mixed (at least 2 sites)         4 (2)         1 (2)
Lesion or swelling (abscess or lump)   1 (0.5)         1 (2)
Others 4 (2)  4 (7.4)
Erythrocyte sedimentation rate (ESR)
≥10 mm in the first hour 182 (92)  52 (96.3)
<10 mm in the first hour     1 (0.5)            -
No information 15 (7.5) 2 (3.7)
X-ray findings
Not available          - 1 (2)
Normal finding          - 12 (22.2)
Abnormalities
Opacity (≥2 lobes = 116)    116 (58.6)          -
Cavity (one = 1)        1 (0.5)          -
Opacity and cavity (1 lobe involvement)      61 (30.8)          -
Pleural effusion (uni =18; bilateral = 4)      17 (8.6)       5 (9.3)
Fibrotic changes        1 (0.5)          -
Pneumothorax        1 (0.5)          -
Spine        3 (1.5)       6 (11.1)
Miliary          - 30 (55.6)
Other results: CT scan, MRI, ultra-sound, echocardiogram, 2 (1)       4 (2)
   PCR and opthalmoscopic  examination
Sputum smear positive for AFB
Positive       67 (33.8)       7 (13)
Negative     125 (63.1)     44 (81.4)
No information         6 (3.0)       3 (5.6)
Sputum culture positive for M. tuberculosis
Positive       98 (49.5)     15 (27.8)
Negative       76 (38.4)     29 (53.7)
No information       24 (12.1)       9 (16.7)
Fluid analysis (smear, culture and biochemical analysis)
Positive          - 1 (1.8)
No information     198 (100)     53 (98.2)
Tissue biopsy
Positive lymph node         5 (2.5)       6 (11.1)
Positive pleura         - 2 (3.7)
Positive intestine        1 (0.5)          -
No information    192 (97)     46 (85.2)
CD4 cell count      25 (12.6)     10 (18.5)
Range 0-1,179, median = 57 cell/mm3
<200     18 (9.1)     10 (18.5)
200-499       3 (1.5)          -
≥500 4 (2)          -
ap< 0.05 for differences between PTB and ETB groups by χ2 test.
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higher success rate in the PTB patients
(42%). More EPT patients (43%) had treat-
ment success with a longer duration (9
months) of therapy than the other regimens.
Defaulting treatment was the most common
type of nonadherence to anti-tubercular
therapy in both groups of TB patients.
There was no MDR-TB or relapse cases
found during this study. Unfortunately, 9
patients died, of which 8 patients had only
tuberculosis and 1 patient had tuberculo-
sis with MRSA and septicemia.
DISCUSSION
Pulmonary tuberculosis was the most
common disease location found among the
patients in this study. This finding is in
agreement with those reported in the lit-
erature (Whalen et al, 1997; Lado Lado et
al, 1998; Perlman et al, 1999; Chakraborty
and Chakraborty, 2000). However, it is con-
trary to some other studies (Vazquez et al,
1994; Sudre et al, 1996; Sharma et al,
1997; Chiu et al, 1999; Inverarity et al,
Table 3
The anti-tuberculous therapy and outcomes of TB/HIV patients.
Duration PTB (198) EPT (54) Total
n (%) n (%)
At least 6 months
Treatment success/completed
6 months      28 (42)     8 (38)       36
9 months      25 (37)     9 (43)       34
12 months      14 (21)     4 (19)       18
Total      67 (100)   21 (100)       88
Less than 6 months
Continuing      12 (37.5)     3 (50)       15
Transferred out      20 (72.5)     3 (50)       23
Total      32 (100)     6 (100)       38
Nonadherence
Defaulted      79 (87)   21 (81)     100
Absconded        1 (1)     1 (4)         2
Drug allergy      11 (12)     4 (15)       15
Total      91 (100)   26 (100)     117
Death
Tuberculosis-related        8 (100)       - 8
AIDS-related            - 1 (100)         1
Total 8 (100)     1 (100)         9
Pulmonary tuberculosis
177 (89.4)
Extrapulmonary tuberculosis
54 (21.4)
Disseminated tuberculosis
21 (10.6)
Lung + one site of involvement
Lung + lymph node
13 (6.6)
Lung + pleura
2 (1)
    Lung + spine
4 (2)
Lung + abdomen
1 (1)
Lung + ≥2 sites of involvement
1 (1)
Miliary/disseminated
30 (55.6)
Lymph node
12 (22.2)
Spine
6 (11.1)
Pleura
5 (9.3)
Pericardium
1 (2)
252 TB/HIV patients 
n (%) 
Fig 1–Disease location of 252 TB/HIV patients.
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2002; Song et al, 2003). HIV is regarded as the
most devastating infection that has caused a re-
surgence of tuberculosis, and continues to be a
real time challenges. We suggest that self-health
awareness be included in TB control programs
particularly in highly prevalent areas of patients
with coexisting tuberculosis and HIV infection.
Cough, loss of appetite and/or weight, and fe-
ver were the main clinical presentations seen in
these patients. These findings are in agreement
with those reported in a previous study (Kimerling
et al, 2002). This indicates that most cases of
tuberculosis are pulmonary, therefore, physicians
should aggressively pursue a diagnosis of TB in
HIV infected patients presenting with respiratory
symptoms in which fever and cough predomi-
nate (Pedro-Botet et al, 1992). We also found
that more than half of these patients had post-
primary TB as opacities with or without cavita-
tion, which was the most common abnormal
radiologic finding. This suggests that routine
chest x-rays should be used to screen all newly
diagnosed HIV-infected patients in order to ob-
tain baseline data, and to further evaluate the
risk-group of the patient. HIV-infected patients
with TB and CD4 cell counts of less than 200
cells/mm3 or those receiving HARRT frequently
present with post-primary patterns (Asimos and
Ehrhardt, 1996; Busi Rizzi, 2003). Our data
showed that only 18 patients with PTB had CD4
cell counts of <200 cells/mm3, and only 3 pa-
tients were receiving antiviral therapy. This sug-
gests that further studies need to be done in
order to evaluate these associations. We further
support the prevention in TB/HIV-infected pa-
tients with isoniazid prophylaxis; which has been
practically recommended in many settings.
In this study, the incidence of extrapul-
monary tuberculosis was 21.4%; miliary tuber-
culosis was surprisingly the more common site
of involvement found among these patients, fol-
lowed by lymph nodes and spine. This finding is
in agreement with one earlier study (Hill et al,
1991). Miliary tuberculosis is a life-threatening
disease resulting from the hematogenous spread
of Mycobacterium tuberculosis, and may present
as an unusual cause of acute respiratory dis-
tress syndrome (Kim et al, 2003). Over the past
two decades, the incidence of extrapulmonary
tuberculosis has not only increased at an even
faster rate than of pulmonary tuberculosis, but
is also considered a diagnostic criterion for ac-
quired immunodeficiency syndrome. The inci-
dence of severe cases, which include miliary tu-
berculosis, tuberculous meningitis, and other
extrapulmonary tuberculosis cases is high among
AIDS-related tuberculosis patients (Elder, 1992;
Nagai, 2003). In the US, 36.9% of HIV-infected
persons with EPT had miliary tuberculosis (Barnes
et al, 1993). From this study, we found that in the
sex distribution of extrapulmonary tuberculosis
among these patients, 87% were men, intrave-
nous drug users and of a specific racial origin.
These risk factors were also noted by other in-
vestigators (Slutsker et al, 1993). This indicates
that certain socioeconomic risk factors still play
an important role in contributing to the course
of disease. Extrapulmonary tuberculosis is a
public health concern in Malaysia, and will be-
come more prevalent along with the incidence
of HIV-infected patients, as has been occurring
over the past few years.
As for the role of immune status, 35 pa-
tients with CD4 cell counts were found in the
medical record. In 25 PTB patients, 18 had CD4
cell counts of less than 200 cells/mm3, and 7
cases had either a CD4 cell count between 200-
499 or ≥ 500 cells/mm3. Ten patients with EPT
had CD4 counts of less than 200 cells/mm3 at
the time of the diagnosis. Our findings show that
patients who had very low CD4 counts were
more likely to develop extrapulmonary tubercu-
losis than those higher counts. This has also
been documented in other studies (Ackah et al,
1995; Castilla et al, 1997; Lee et al, 2000). We
conclude that the CD4 count is recommended
as a prognostic marker, indicating the severity
of immune deficiency, which determines the
morbidity and mortality in HIV-related tubercu-
losis patients. In addition, a paradoxical reac-
tion to antituberculous therapy after immuno-
restoration is induced by combined antiviral
therapy has also been reported (Gerard, 2000).
Our results show that not even half the to-
tal number or these patients with tubrerculosis
completed treatment or were declared as a cure.
This observation is the same as in other settings.
We found that most patients with PTB were suc-
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cessfully treated with 6 months short-course
therapy, compared to patients with EPT who
took a longer time, at least 9 months. This ob-
servation is consistent with other studies
(Gerard, 2000; Wang et al, 2000). This is due to
the fact that extrapulmonary tuberculosis can be
rapidly fatal but is a treatable condition, there-
fore diagnostic procedures should be imple-
mented early and empirical treatment given in
suspected cases. We found that nearly half of
patients with either PTB or EPT were noncom-
pliant with therapy; a slightly higher rate was
seen in patients with PTB. The factors that may
contribute to nonadherence in this study were
being male, having a low socioeconomic status,
being single, being an injecting drug user, and
having certain racial origins (data were not shown).
These findings are supported by other previous
investigations (Tansuphaswadikul et al, 1998;
Wobeser et al, 1999; Tanguis et al, 2000; Santha
et al, 2002). Nonadherence to anti-tubercular
therapy has a significant impact on, and is a long-
standing problem for involved medical personnel
in Malaysia; a country considered to be an inter-
mediate zone of tuberculosis burden. Nonadher-
ence may contribute to the spread of tuberculo-
sis and the emergence of drug resistance, and
may increase the cost of treatment (Pablos-
Mendez et al, 1997) and relapses (Brucker-Davis
et al, 1993). The special problem of prophylaxis
of persons exposed to multidrug-resistant tuber-
culosis is important (Sepkowitz et al, 1995). DOT
programm has been implemented for all TB pa-
tients in Malaysia. In TB/HIV-infected patients with
history of nonadherence to antitubercular therapy
for any cause, closer monitoring is carried out by
medical personnel in this center.
Tuberculosis is very common in Malaysia.
Pulmonary and extrapulmonary tuberculosis pre-
dominantly occurs in men, of certain racial ori-
gins, low socioeconomic status, and in intrave-
nous drug users. Lung and miliary were the most
common sites of involvement in pulmonary and
extrapulmonary tuberculosis, respectively. Most
PTB patients were treated successfully treated
with 6 months short-course therapy. Nonadher-
ence to anti-tubercular therapy was noted more
frequently in patients with pulmonary tuberculo-
sis.
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